Health and Wellbeing Board



Date of meeting: 24 July 2024

Title of Report: Plymouth Drugs Strategic Partnership Annual Report

2024

Lead Member: Councillor Mrs Mary Aspinall (Cabinet Member for Health and Adult

Social Care)

Lead Strategic Director: Ruth Harrell (Director of Public Health)

Author: Kamal Patel, Consultant in Public Health

Contact Email: Kamal.Patel@Plymouth.gov.uk

Your Reference:

Key Decision: No

Confidentiality: Part I - Official

Purpose of Report

To provide to the Health and Wellbeing Board the Annual Report of the work of the Plymouth Drugs Strategic Partnership in 2023.

Recommendations and Reasons

I. That the Plymouth Health and Wellbeing Board note the report and provide any comment or feedback on the Plymouth Drugs Strategic Partnership.

Alternative options considered and rejected

N/A

Relevance to the Corporate Plan and/or the Plymouth Plan

Plymouth Corporate Plan:

- Working with the Police to tackle crime and antisocial behaviour
- Working with the NHS to provide better access to health, care and dentistry
- Keeping children, adults and communities safe
- Providing quality public services
- Focusing on prevention and early intervention

The Plymouth Plan:

- HEA1: Addressing health inequalities, improving health literacy
- HEA3: Supporting adults with health and social care needs
- HEA5: Delivering strong and safe communities and good quality neighbourhoods
- HEA9: Delivering accessible health services and clinical excellence

Implications for the Medium Term Financial Plan and Resource Implications:

N/A – this is a report on an existing programme of work

Financial Risks

None

Carbon Footprint (Environmental) Implications:

N/A

Other Implications: e.g. Health and Safety, Risk Management, Child Poverty:

* When considering these proposals members have a responsibility to ensure they give due regard to the Council's duty to promote equality of opportunity, eliminate unlawful discrimination and promote good relations between people who share protected characteristics under the Equalities Act and those who do not.

N/A

Appendices

*Add rows as required to box below

Ref.	Title of Appendix	If some why it is	Exemption Paragraph Number (if applicable) If some/all of the information is confidential, you must indicate why it is not for publication by virtue of Part 1 of Schedule 12A of the Local Government Act 1972 by ticking the relevant box.						
		ı	2	3	4	5	6	7	
A	Plymouth Drugs Strategy Partnership Annual Report 2024								
В	Plymouth Drugs Strategy Partnership Annual Report 2024 (presentation)								

Background papers:

Please list all unpublished, background papers relevant to the decision in the table below. Background papers are <u>unpublished</u> works, relied on to a material extent in preparing the report, which disclose facts or matters on which the report or an important part of the work is based.

Title of any background paper(s)	Exemption Paragraph Number (if applicable)						le)
	If some/all of the information is confidential, you must indicate why it is not for publication by virtue of Part 1 of Schedule 12A of the Local Government Act 1972 by ticking the relevant box.						
	ı	2	3	4	5	6	7
N/A							

Sign off:

Fin	N/A	Leg	N/A	Mon Off	N/A	HR	N/A	Asset s	N/A	Strat Proc	N/A
Originating Senior Leadership Team member: Ruth Harrell											
Please confirm the Strategic Director(s) has agreed the report? Yes											
Date agreed: 12/07/2024											

^{*}Add rows as required to box below

Cabinet Member approval: Yes – approved verbally

Date approved: 12/07/2024